A detailed history of Putnam Investments LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Putnam Investments LLC holds 66,516 shares of PRTA stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,516
Previous 56,613 17.49%
Holding current value
$1.18 Million
Previous $2.73 Million 11.5%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$32.31 - $52.32 $319,965 - $518,124
9,903 Added 17.49%
66,516 $2.42 Million
Q3 2023

Nov 14, 2023

BUY
$47.3 - $70.6 $183,760 - $274,281
3,885 Added 7.37%
56,613 $2.73 Million
Q2 2023

Aug 14, 2023

BUY
$48.26 - $78.59 $87,977 - $143,269
1,823 Added 3.58%
52,728 $3.6 Million
Q1 2023

May 22, 2023

SELL
$46.97 - $58.27 $680,548 - $844,274
-14,489 Reduced 22.16%
50,905 $2.47 Million
Q4 2022

Feb 14, 2023

BUY
$52.05 - $65.0 $2.64 Million - $3.29 Million
50,638 Added 343.17%
65,394 $3.94 Million
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $32,003 - $77,121
1,272 Added 9.43%
14,756 $894,000
Q2 2022

Aug 15, 2022

BUY
$22.73 - $39.98 $30,390 - $53,453
1,337 Added 11.01%
13,484 $366,000
Q1 2022

May 16, 2022

BUY
$30.27 - $49.22 $18,706 - $30,417
618 Added 5.36%
12,147 $444,000
Q4 2021

Feb 14, 2022

BUY
$42.11 - $73.26 $485,486 - $844,614
11,529 New
11,529 $570,000
Q4 2017

Feb 14, 2018

SELL
$35.44 - $63.76 $9.19 Million - $16.5 Million
-259,387 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$53.83 - $67.75 $14 Million - $17.6 Million
259,387
259,387 $16.8 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $831M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Putnam Investments LLC Portfolio

Follow Putnam Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Putnam Investments LLC with notifications on news.